EVGEN PHARMA PLC LS-0025
Research EVGEN PHARMA PLC LS-0025 (8EV) on Bullrun: market cap EUR 5.29M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker8EV
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 5.29M
- Financial periodFY2025
- RevenueGBP 0
- Revenue growth-100.0%
- Net income-GBP 1.94M
- Free cash flow-GBP 2.37M
Valuation Snapshot
latest market cap is EUR 5.29M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 0 | -GBP 1.94M | -GBP 2.37M | n/a | 0 | GBP 2.11M | n/a | GBP 5.97M |
| FY2024 | GBP 396.00K | -GBP 3.14M | -GBP 3.00M | n/a | -0.01 | GBP 2.00M | n/a | GBP 2.34M |
| FY2023 | GBP 442.00K | -GBP 4.04M | -GBP 4.13M | n/a | -0.01 | GBP 5.00M | n/a | GBP 5.34M |
| FY2022 | GBP 0 | -GBP 2.73M | -GBP 2.59M | n/a | -0.01 | GBP 4.51M | n/a | GBP 9.23M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 5.29M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About EVGEN PHARMA PLC LS-0025
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is EVGEN PHARMA PLC LS-0025's market cap?
EVGEN PHARMA PLC LS-0025's market capitalization is EUR 5.29M.
What does EVGEN PHARMA PLC LS-0025 do?
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024.